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Summary In recent years, radiolabelled monoclonal antibodies have been evaluated for their use in the
diagnosis and treatment of neoplastic disease. One isotope which has not been assessed for antibody targeting
iS 32P, even though it has many favourable radiobiological characteristics and has been used clinically for the
treatment of certain neoplastic disorders such as polycythaemia rubra vera. The main drawback so far in
using 32P has been the absence of a general method for phosphorylating antibodies. We have now developed
a novel process for the phosphorylation of immunoglobulins which is rapid, efficient and allows high specific
activities to be achieved (>l10Ciyg-1). The technique involves the chemical conjugation of Kemptide, a
synthetic heptapeptide substrate for kinases, to immunoglobulins. The antibody-Kemptide conjugate can then
be phosphorylated using protein kinases and [32P1-y-ATP. The procedure does not compromise the binding
activity of the antibody. The 32P-labelled monoclonal antibodies were stable in human, mouse and rat
plasmas in vitro, although they cleared from the bloodstream of mice with a fl-phase half life of 2 days which
is approximately two times faster than that of native antibody. The application of this phosphorylation
technique should allow the therapeutic potential of targeted 32P to be assessed.
The concept of using monoclonal and polyclonal antibodies
to deliver cytotoxic amounts of radiation is now being tested
clinically by giving 1311-labelled monoclonal antibodies by
the intravenous (Order et al., 1981; Ettinger et al., 1982;
Larsen et al., 1983), intraarterial (Epenetos et al., 1985) and
intracavitary (Courtenay-Luck et al., 1984) routes. Although
131I-iodine is not an ideal isotope for antibody targeting,
because of its gamma emissions and the high levels of in vivo
deiodination (Halpern et al., 1981; Sullivan et al., 1982),
there are still many reasons for its popularity. Most
important of these are the availability of protein iodination
techniques that are rapid, simple, give high specific activities
and which do not damage significantly the antibodies'
biological function.
Recently, however, a novel method for the covalent
coupling of the strong chelating group diethylenetri-
aminepentaacetic acid (DTPA) to antibodies has been
developed (Hnatowich et al., 1983a; Scheinberg et al., 1982;
Paxton et al., 1985) which allows antibodies to be labelled
with metallic radionuclides such as "'1In (Hnatowich et al.,
1983a, b; Scheinberg et al., 1982; Paxton et al., 1985)
and 99mTC (Lanteigne & Hnatowich, 1984).
More recently another metallic radionuclide, 90Y, has been
used to label DTPA-linked antibodies (Hnatowich et al.,
1985) and promising radioimmunotherapeutic results have
been reported (Order et al., 1986). This isotope is of
considerable interest because of its pure f-ray particle
emission, high emission energy, half-life and stable daughter
products. However the use of 90Y does have disadvantages
requiring the availability of a 90Sr-90Y generator and, in
common with other chelated metallic radionuclides, there is
a loss of 90Y from the antibody and large uptake by liver,
kidneys, bone and bone marrow (Hnatowich et al., 1985).
Another isotope with many of the ideal propeties of 90Y is
32p. Though having a longer half-life (14 days) than 90Y,
this isotope has been used clinically in cancer therapy for
many years (Today's drugs, 1967; Boye et al., 1984). The
0.6cm tissue path length of the 32P-fl-ray may be
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advantageous for attacking tumours with low vascularity.
Until now there has been no simple method for conjugating
32p to antibodies. In this communication we describe a
simple, rapid procedure for phosphorylating antibodies
which allows high specific activities to be achieved without
any significant impairment of antibody function. Kemptide
(Kemp et al., 1976), a heptapeptide substrate (Leu. Arg. Arg.
Ala. Ser. Leu. Gly) for the cAMP-dependent protein kinase,
is first covalently linked to the antibody and then
phosphorylated with 32P-y-ATP and protein kinase. The
antibody 32P-Kemptide conjugates show no impairment of
antibody function, are stable in serum, and have a slow rate
of clearance in mice (t,,2=2 days).
Materials and methods
Reagents
Monoclonal antibody secreting hybridomas were kindly
provided by the following: OX7, Dr A.F. Williams (MRC,
Cellular Immunology, University of Oxford); LICR-LON-
RIO, Dr P.W. Edwards, (Ludwig Institute, Sutton, UK);
H17E2, Dr W.F. Bodmer (ICRF), HMFG2, Dr J. Taylor-
Papadimitriou (ICRF).
Cell lines were kindly provided by the following: AKR-A,
Thy 1.1 lymphoma, Prof. I. Maclennan (Birmingham
University, UK); HEp-2 (Flow Laboratories,
Rickmansworth, England); K562, Dr B. Lozzio (University
of Memphis, Tennessee, USA); EL-4 cells, Dr F. Spencer
(Institute of Cancer Research, Sutton, UK).
Tissue culture medium RPMI 1640 and foetal calf serum
were obtained from Gibco-Biocult Ltd. (Paisley, Scotland).
Sodium [1251] Iodide (IMS30) and [32P]-y-ATP (PB 10218)
were obtained from Amersham International (UK).
The lodogen reagent was obtained from Pierce (UK) Ltd.
(Chester, England). Sephadex G50 and N-succinimidyl-3-(2-
pyridyldithio)propionate (SPDP) were obtained from
Pharmacia Ltd. (Milton Keynes, England). Kemptide and
bovine heart cAMP-dependent protein kinase catalytic
subunit were obtained from Sigma (Poole, Dorset, UK).
Purified catalytic subunit was also prepared according to the
method of Beavo et al. (Beavo et al., 1974). Cellulose thin
layer chromatography plates (6065) were purchased from
Eastman Kodak. Fluorescence-conjugated (FITC) rabbit
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antimouse IgG was obtained from Miles (UK) Ltd. (Slough,
UK).
N-succinimidyl iodoacetate ester was synthesised as
described previously (Rector et al., 1978).
All other reagents were of analytical grade or better.
Buffer solutions Four buffers were used during the
preparation of the conjugates: (a) 0.05 M sodium borate
pH9.0, containing 0.1 MNaCl and 0.5% (v/v) n-butanol; (b)
0.1 M sodium acetate, pH4.5, containing 0.1 MNaCl and
1 mM EDTA; (c) 0.1 M sodium phosphate buffer, pH7.5
containing 0.1 MNaCl and 1 mM EDTA; (d) enzyme buffer,
50mM sodium phosphate pH7.0, containing 5mM MgCl2
and 0.25mM EGTA.
HPLC measurements of immunoglobulins and conjugates
were carried out on a 7.5 x 300mm LKB Ultropac column
(TSK G3000 SW) using 0.1 M K H2PO4 (pH6.0) as the
isocratic eluant with a DuPont 870 Pump System.
The preparation of Kemptide-IgG conjugates
The method of conjugation depends on the reaction of
iodoacetyl groups introduced into the Kemptide with thiol
groups introduced into the immunoglobulin. It is similar in
principle to the method of protein-protein coupling
developed by Rector et al. (1978).
Introduction of an iodoacetyl group into Kemptide was
performed as follows: N-Succinimidyl-2-iodoacetate
(0.75mg) in dry dimethyl formamide (DMF, 62.5M1) was
added to a solution of Kemptide (1.5mg) in water (60pl)
which had first been diluted with methanol (40p1). After
incubation for 1 h at room temperature, the reaction was
shown to be complete by analysis of a sample by thin layer
chromatography (Rector et al., 1978). The absence of
ninhydrin-staining material demonstrated the removal of the
free primary amino group. The reaction mixture was then
used directly for coupling to the thiopropionylated antibody
as described below.
The thiopropionylation of monoclonal antibody OX7 and
subsequent coupling with iodoacetyl Kemptide was
performed as follows: a solution of SPDP (129u1 of a stock
solution of 3.6mgml -1 in dry DMF) was added to a
solution of antibody (27.22mg) in borate buffer. The molar
ratio of SPDP to immunoglobulin was eight. After
incubation at room temperature for 1 h, the reaction mixture
was desalted on a G50 Sephadex column (60ml) which had
been equilibrated in acetate buffer. Analysis of the eluted
protein by the standard method of Carlsson et al. (1978)
revealed that 4.6 dithiopropionyl groups had been
introduced per IgG molecule. Approximately half the protein
solution was then incubated with dithiothreitol (final
concentration 50mM) for 1 h at room temperature and then
desalted on a G50 Sephadex column (60ml) equilibrated in
nitrogen-flushed phosphate buffer. The eluted protein was
immediately concentrated by Amicon ultrafiltration to
1.65ml (6.8mgml-1). To this solution was immediately
added dry DMF (400p1) followed by the iodoacetylated
Kemptide solution (40p1, prepared as described above). The
reaction mixture was incubated at room temperature for 24h
and any remaining unreacted thiol groups blocked by the
addition of an excess of N-ethylmaleimide (5mg) in DMF
(100p1). After a further hour, the reaction mixture was
applied to G50 Sephadex column (60ml) equilibrated in the
enzyme buffer. The number of Kemptide groups able to
accept a phosphate group linked to each antibody molecule
was shown to be approximately 2 by trace-labelling studies
(see Table I). The above method was also used for the
conjugation of monoclonal antibodies RIO, H17E2 and
HMFG2 and bovine IgG fraction (Sigma).
Phosphorylation of OX7-Kemptide For high specific activity
labelling, OX7-'Kemptide' (50 ul, 1 mgml -1)andenzymebuffer
(12.5 p1 at 5 times concentration) were added to 1 mCi of
[32P]-y-ATP (1O00pl), followed by bovine protein kinase (5M1,
50U). The reaction was incubated at 37°C for 30min
followed by removal of unreacted ATP using a G50
Sephadex column (10ml) equilibrated in phosphate-buffered
saline which had been prewashed in PBS containing bovine
serum albumin (2mgml-P). Routinely, between 30-40% of
the 32P was bound to the conjugate by this process giving
specific activities between 5-10pCipg-1.
For trace-labelling studies, the antibody or conjugate
(1 nmol) was treated with ATP (25nmol), [32P]-y-ATP
(0.5pCi) and bovine heart cAMP-dependent protein kinase
catalytic subunit (50U) in a total volume of 150pl. After
incubating at 37°C for 30min, 10pl samples were taken and
added to 100lp1 bovine serum albumin (2mgml-1) in
phosphate buffered saline immediately followed by IOOIp
20% trichloroacetic acid. The precipitated protein was
collected on GF/C filters (Whatman) and the 32P counted in
2ml of Optiphase. Total counts were obtained by adding
10pi of the reaction mixture to 2ml Optiphase. The number
of phosphate groups incorporated per IgG molecule (P/Ig)
was then calculated. Background levels of phosphorylation
obtained from incubations without antibody or conjugate
were subtracted.
FACS analysis of antibody-Kemptide cell binding Solutions
of OX7-Kemptide conjugate (50pl) at various concentrations
were added to aliquots of AKR-A mouse lymphoma cells
(1 ml at 106 cellsml-1) in phosphate buffered saline (PBS)
containing bovine serum albumin (BSA, 2mgml-1) and
sodium azide (0.05%). After incubation at 37°C for 30min,
the cells were washed twice with the PBS-BSA-azide solution
and the resultant cell pellets treated with FITC-rabbit
antimouse antibody (100p1, diluted 1:32) for 30min. The
cells were then washed in PBS-BSA-azide three times and
finally suspended in the buffer solution (1 ml). Flow
cytometry analysis of at least 104 cells at each concentration
was performed using a FACS I (Becton Dickinson).
Stability ofphosphorylated conjugates in human, mouse
and rat plasma
Plasma was collected from heparinized blood taken from nu/
nu mice, Sprague-Dawley rats or human volunteers.
Aliquots (0.5ml) of each plasma sample were mixed with 1 M
sodium phosphate, (125pl, pH7.2) and penicillin/
streptomycin (6pl, Flow Labs Cat. No. 16-700-49). After
sterilisation by filtration through 0.22y filters, the resultant
solutions (450Ml) were incubated at 37°C with equal volumes
of a sterile solution of bovine IgG-32P-Kemptide
(225pgml-1 at 2mCipmol-1 protein) and triplicate samples
(20Ml) were taken at a range of time points over a 64h
period. Acid precipitates obtained by treatment with 20%
trichloroacetic acid were collected on glass fibre filters and
counted with 2ml of Optiphase (Fisons plc, Loughborough,
UK) in a LKB Rackbeta scintillation counter.
Blood clearance of antibody 32P-Kemptide conjugates in
mice
For blood clearance studies, BALB/c mice (4/group) were
injected i.v. with either radioiodinated OX7 antibody, radio-
iodinated OX7-Kemptide or OX7-32P-Kemptide, and blood
samples taken at various periods of time later. After
centrifugation to sediment cells, the protein in 10pl samples
of plasma was precipitated with 20% trichloroacetic acid,
collected on glass fibre filters and counted in 2ml Optiphase,
using an LKB Rackbeta scintillation counter.
Results
Synthesis and labelling of antibody-Kemptide conjugates
The method of conjugating monoclonal antibodies to
Kemptide uses the protein-protein coupling chemistry
developed by Rector et al. (1978). Thiol groups are
introduced into the antibody and iodoacetyl groups into the32P-ANTIBODY LABELLING 491
Kemptide which, together react to form a protein/peptide
conjugate in which the linkage is a thioether bond:
Ig-NH.CO.CH2.CH2.S.CH2.CO.NH Kemptide.
The success of using this procedure to link different
monoclonal antibodies to Kemptide is shown by the results
of trace-labelling studies summarised in Table I. After
conjugation to Kemptide, monoclonal antibodies OX7,
HMFG-2 and H17E2 were able, in the presence of protein
kinase, to accept approximately 2 phosphate groups per IgG
molecule from ATP, whereas the unconjugated antibodies
were not labelled at all. The RlO-Kemptide conjugate could
only be labelled with 0.7 phosphate groups per IgG
molecule. The results obtained with the conjugates minus
enzyme (Table I) clearly show that the labelling of
conjugates is not due to an artifactual non-specific
association of 32P-y-ATP with the conjugate.
Analysis of OX7-32P-Kemptide by HPLC showed that
95% of the radioactivity applied to the column co-migrated
with OX7-Kemptide. Both the 32P-labelled and unlabelled
conjugates had a mobility the same as OX7 and showed no
evidence of the presence of significant amounts of dimers or
larger polymers (Figure 1). The remaining activity had the
mobility of (and most probably was) unreacted 32P-y-ATP.
Further HPLC analysis of a moderately labelled 0X7-32P-
Kemptide sample (3pCigg-' protein) stored in 2mgml-1
BSA in phosphate-buffered saline at 40C demonstrated that
there was no rapid dephosphorylation of the conjugate over
a 72h period nor was there any evidence of gross radiolytic
damage to antibody by the production of labelled antibody
fragments.
Kinetic studies on the rapidity of phosphorylation of
antibody-Kemptide conjugates have indicated that labelling
is complete within 15min (not shown).
Effect of conjugation on antibody-antigen recognition
Measurements of the binding of OX7 and OX7-Kemptide to
AKR-A lymphoma cells using the FACS (Figure 2) showed
that there was no detectable impairment of antigen-binding
capacity after the conjugation procedure. The proportions of
OX7 and OX7-Kemptide that gave 50% maximal binding
was ca. 100ng 10-6 cells. The results presented in Figure 3
demonstrate the specificity of antibody-targeted 32P_
phosphate. A comparison of 32P-targeting between
Kemptide conjugates of OX7 and H17E2 antibodies on
AKR-A cells (Figure 3) again demonstrates that only the
specific OX7 antibody will allow the localisation of the
radionuclide onto the target cell. Further, OX7-32P-
Kemptide did not bind detectably to Thy 1.2-expressing EL4
Table I Phosphorylation of conjugates
Substrate + Enzyme P/IgG
OX7 + 0.0
OX7-Kemptide - 0.0
OX7-Kemptide + 2.2
H17E2 + 0.0
H17E2-Kemptide - 0.0
H17E2-Kemptide + 2.05
RIO + 0.0
R1O-Kemptide - 0.0
R1O-Kemptide + 0.7
HMFG2 + 0.0
HMFG2-Kemptide - 0.0
HMFG2-Kemptide - 1.82
A variety of different antibodies and conjugates
were subjected to the phosphorylation procedure with
trace amounts of 32P-y-ATP in the presence or absence
of the enzyme as described in Materials and methods.
The acid-precipitable radioactivity was measured and
the ratios of phosphate groups per IgG molecules
calculated.
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.Figure 1 HPLC analysis of OX7-Kemptide conjugate. A 50pM
sample of the conjugate in enzyme buffer (pH 7.0) was analysed
on a TSK G3000 SW column as described in Materials and
methods. The radioactivity of 1 ml fractions was counted and the
uv absorption recorded. Native OX7 had a mobility identical to
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Figure 2 Comparison of the binding of OX7 and OX7-
Kemptide to AKR-A lymphoma cells measured by indirect
immunofluorescence. The binding of OX7 and OX7-Kemptide to
AKR-A cells was measured by indirect immunofluorescence and
FACS analysis as described in Materials and methods. Cells
treated with FITC-labelled anti-mouse IgG alone showed a mean
fluorescence intensity which did not exceed 20 at any
concentration.
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Figure 3 Comparison of the binding of OX7-32P-Kemptide and
H17E2-32P-Kemptide to AKR-A lymphoma cells. To 106 AKR-
A cells (107 m -I1 PBS containing 2mgml - BSA and 0.02%
sodium azide) were added 100up1 of either conjugate at various
concentrations. The cells were kept on ice for 1h and then
pelleted through 100p1 oil (a blend of 84% 550 and 16% 200/2cs
Silicone oil (Dow Coming)) by centrifugation for 90 sec at
12000g. The centrifuge tubes were frozen on dry ice, the tips
containing the cell pellets removed and counted in 2ml
Optiphase.
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cells (results not shown). Similar studies with HI7E2-
Kemptide on placental alkaline phosphatase-expressing
HEp2 cells and R10-Kemptide on glycophorin-expressing
K562 cells have also shown no impairment of antibody
function after conjugation (results not shown).
Stability of conjugates in plasma and blood clearance of the
OX7-Kemptide conjugates
Incubation of a 32P-labelled bovine Ig-Kemptide conjugate
in samples of murine, rat and human plasma for up to 64h
(see Materials and methods) gave no indication of dephos-
phorylation of the conjugate indicating the absence of any
Kemptide-recognising phosphatases in the isolated plasma of
humans, rats or mice.
In the murine blood clearance study, plasma samples were
taken at various time intervals following the injection (i.v.)
of either OX7-32P-Kemptide or 125I-OX7-Kemptide into
mice, and either assessed for acid-precipitable radioactive
material or analysed by HPLC. The half-life of OX7-32P-
Kemptide in the blood as assessed by acid-precipitation was
2.0 days for the fl-phase clearance (Figure 4). This is much
shorter than the 4.0 day half-life for 125I-labelled OX7
(Figure 4). Since in parallel studies, 125I-labelled OX7-31P-
Kemptide was found to have a half-life of 2.8 days, it seems
likely that the shorter half-life of OX7-32P-Kemptide is
related to the enhanced clearance of the conjugate compared
with the native antibody rather than being the result of
dephosphorylation. HPLC analysis of the plasma samples
showed that the 32P remained associated with protein which
co-migrated with OX7-antibody (not shown).
Discussion
Kemptide, a synthetic heptapeptide substrate for protein
kinases, has been covalently bonded to monoclonal
antibodies to provide phosphorylatable immunoglobulins
which can be used to assess the tumoricidal potential of
antibody-targeted 32P. The conjugation method uses the
protein-protein coupling chemistry developed by Rector et
al. (1978) which has been employed recently to produce
antibody-ricin immunotoxins (Thorpe et al., 1984). Four
different monoclonal antibodies as well as a bovine immuno-
globulin fraction have been conjugated to Kemptide by this
process and as a result are able to accept 1-2 phosphate
groups per immunoglobulin molecule from ATP in the
presence of appropriate kinases. Using carrier-free 32P_-_
ATP (specific activity >5000Cimmol-1), phosphorylated
antibodies with a specific activity of 104Ci g-1 have been
achieved. Potentially this could be increased to a theoretical
maximum of 30-60pCipg-1 if saturation of all the
available phosphorylation sites were attained.
None of the antibody-Kemptide conjugates synthesised so
far have shown any reduction in antigen-binding activity and
thus it seems likely that this conjugation procedure could be
usefully extended to other monoclonal antibodies and to
non-immunoglobulin proteins as well. The ability of
antibody-Kemptide conjugates to act as substrates for
protein kinase would also suggest that there is no major
impairment of Kemptide phosphate acceptor function
although this has not been assessed in detail. The possibility
that the phosphorylation of conjugates was a consequence of
the conjugation procedure revealing hitherto occluded
phosphorylation sites in the antibody molecule was
discounted since antibodies that had been through the
conjugation procedure in the absence of Kemptide could not
be phosphorylated.
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Figure 4 Blood clearance rates of 125I-OX7, OX7-32P-Kemptide
and 125I-OX7-Kemptide. The clearance of OX7 and OX7-
Kemptide from the murine bloodstream was measured as
described in Materials and methods. The radioactivity in the
plasma is expressed as a percentage of the To value, the level at
10min post injection.
Studies on the antibody-directed localisation of 32P onto
cells clearly showed that the binding of 32P-labelled antibody
required the presence of the antigen recognised by the
targeting antibody. Non-specific targeting of 32P by
antibody-Kemptide conjugates was found to be negligible.
Studies of the stability of antibody-32P-Kemptide
conjugates in plasma in vitro show that there is no rapid
dephosphorylation of the conjugate by putative plasma
phosphatases. However investigation of the blood clearance
of OX7-32P-Kemptide in mice showed that the #-phase half-
life of the conjugate was only 2.0 days as compared with 4.0
days for l25I-labelled OX7. Parallel studies with 12 II-labelled
OX7-31P-Kemptide showed that its blood half-life was only
2.8 days. This demonstrates that OX7-Kemptide is cleared
more rapidly than native antibody and that the enhanced
clearance of the conjugate is not the result of
dephosphorylation. The 0.8 day discrepancy between 32P
and 125I-measured half-lives can be accounted for by the
presence of unconjugated OX7 in the conjugate preparation:
the longer blood survival of 125I-labelled unconjugated OX7
would contribute to the half-lives measured by 1251 but
would not, of course, have affected those based on the
measurement of 32P. The enhanced clearances of antibody-
Kemptide conjugates would suggest that even apparently
minor modifications to the antibody structure can lead to a
faster removal of immunoglobulin from the blood. Since
HPLC analysis showed an absence of significant amounts of
dimers or higher polymers, the enhanced clearance cannot
simply be due to the removal of such aggregates.
Although theroretically it would be more attractive to use
a linkage involving the more stable carbon phosphorus
bond, the preparation of the appropriate reagents at high
specific activities presents special difficulties which will not
be easily resolved. The novel procedure we describe here has
the virtue that it makes use of readily available derivatives of
32P and should allow the therapeutic potential of the
targeted radioisotopes to be assessed. Initial studies (to be
published elsewhere) have shown that these conjugates can
direct 32P to subcutaneous AKR-A tumours achieving
concentrations of up to 12.4% of the injected dose/gram.
Thus we believe that antibody 32P-Kemptide conjugates
represent a new avenue in the development of antibody-
targeted tumoricidal agents.
The authors wish to thank Audrey Becket for typing the manuscript.
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